
Kushtrim Kryeziu
- Researcher; PhD
Publications 2023
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo
Cancer Lett, 565, 216237
DOI 10.1016/j.canlet.2023.216237, PubMed 37211067
Endocytic trafficking of connexins in cancer pathogenesis
Biochim Biophys Acta Mol Basis Dis, 1869 (7), 166812
DOI 10.1016/j.bbadis.2023.166812, PubMed 37454772
Publications 2022
Multiplex immunohistochemistry of metastatic colorectal cancer and ex vivo tumor avatars
Biochim Biophys Acta Rev Cancer, 1877 (1), 188682
DOI 10.1016/j.bbcan.2022.188682, PubMed 35065193
Publications 2021
Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases
J Transl Med, 19 (1), 384
DOI 10.1186/s12967-021-03062-3, PubMed 34496878
The expressed mutational landscape of microsatellite stable colorectal cancers
Genome Med, 13 (1), 142
DOI 10.1186/s13073-021-00955-2, PubMed 34470667
Publications 2020
Patient-Derived Organoids from Multiple Colorectal Cancer Liver Metastases Reveal Moderate Intra-patient Pharmacotranscriptomic Heterogeneity
Clin Cancer Res, 26 (15), 4107-4119
DOI 10.1158/1078-0432.CCR-19-3637, PubMed 32299813
Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
EBioMedicine, 59, 102923
DOI 10.1016/j.ebiom.2020.102923, PubMed 32799124
Publications 2019
Combination therapies with HSP90 inhibitors against colorectal cancer
Biochim Biophys Acta Rev Cancer, 1871 (2), 240-247
DOI 10.1016/j.bbcan.2019.01.002, PubMed 30708039
Publications 2017
Sensitivity towards the GRP78 inhibitor KP1339/IT-139 is characterized by apoptosis induction via caspase 8 upon disruption of ER homeostasis
Cancer Lett, 404, 79-88
DOI 10.1016/j.canlet.2017.07.009, PubMed 28716523
Colorectal Cancer Consensus Molecular Subtypes Translated to Preclinical Models Uncover Potentially Targetable Cancer Cell Dependencies
Clin Cancer Res, 24 (4), 794-806
DOI 10.1158/1078-0432.CCR-17-1234, PubMed 29242316
[11C]Erlotinib PET cannot detect acquired erlotinib resistance in NSCLC tumor xenografts in mice
Nucl Med Biol, 52, 7-15
DOI 10.1016/j.nucmedbio.2017.05.007, PubMed 28575795
Publications 2016
Macromolecular Pt(IV) Prodrugs from Poly(organo)phosphazenes
Macromol Biosci, 16 (8), 1239-1249
DOI 10.1002/mabi.201600035, PubMed 27169668
Trabectedin Is Active against Malignant Pleural Mesothelioma Cell and Xenograft Models and Synergizes with Chemotherapy and Bcl-2 Inhibition In Vitro
Mol Cancer Ther, 15 (10), 2357-2369
DOI 10.1158/1535-7163.MCT-15-0846, PubMed 27512118
Chronic arsenic trioxide exposure leads to enhanced aggressiveness via Met oncogene addiction in cancer cells
Oncotarget, 7 (19), 27379-93
DOI 10.18632/oncotarget.8415, PubMed 27036042
32nd International Austrian Winter Symposium : Zell am See, the Netherlands. 20-23 January 2016
EJNMMI Res, 6 (Suppl 1), 32
DOI 10.1186/s13550-016-0168-9, PubMed 27090254
Publications 2015
Structure-Related Mode-of-Action Differences of Anticancer Organoruthenium Complexes with β-Diketonates
J Med Chem, 58 (9), 3984-96
DOI 10.1021/acs.jmedchem.5b00288, PubMed 25856666
Publications 2014
Tumor-targeting of EGFR inhibitors by hypoxia-mediated activation
Angew Chem Int Ed Engl, 53 (47), 12930-12935
DOI 10.1002/anie.201403936, PubMed 25079700
Water-Soluble, Biocompatible Polyphosphazenes with Controllable and pH-Promoted Degradation Behavior
J Polym Sci A Polym Chem, 52 (2), 287-294
DOI 10.1002/pola.27002, PubMed 24729657
Publications 2013
Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation
Dalton Trans, 43 (3), 1096-104
DOI 10.1039/c3dt52388h, PubMed 24165902
The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo
Eur J Cancer, 49 (15), 3366-75
DOI 10.1016/j.ejca.2013.05.018, PubMed 23790465
Synergistic anticancer activity of arsenic trioxide with erlotinib is based on inhibition of EGFR-mediated DNA double-strand break repair
Mol Cancer Ther, 12 (6), 1073-84
DOI 10.1158/1535-7163.MCT-13-0065, PubMed 23548265